SUMMARY
intermittment aortic cross-clamping and induced ventricular fibrillation at 32 °C. On the day before surgery, baseline measurements of plasma magnesium, serum potassium, calcium and creatinine kinase (MB fraction) concentrations were obtained and a 12-lead electrocardiogram with derived measurements of QT corr interval was recorded. Patients with preoperative plasma magnesium concentrations outside the reference range (0.74-0.99 mmol litre" 1 ), or those receiving chronic diuretic or specific anti-arrhythmic therapy were excluded. All patients received their normal therapy of beta-adrenergic, calcium antagonist, or both, on the day of operation.
Patients were allocated randomly to receive either magnesium chloride 16 mmol in 10 ml water or placebo (water 10 ml) in a coded ampoule, which was injected to the venous side of the extracorporeal circuit during die first aortic cross-clamp period of cardiopulmonary bypass. The dose of magnesium corresponds to that in one ampoule of St Thomas's Hospital cardioplegic solution. Frusemide 20 mg was given concomitantly, in keeping with routine clinical practice.
The quantities of calcium and potassium and all other drugs, and the volumes of fluids, administered during the study period were recorded. The anaesthetic and postoperative management were similar for all patients, and involved immediate extubation and management in a general surgical recovery ward, as previously described [14] .
Plasma magnesium and potassium concentrations were measured before operation, at the end of bypass, on arrival in the recovery room and at 1, 2, 4, 6 and 24 h after operation. Serum calcium concentration was measured before, and at 6 and 24 h after, operation.
Urinary magnesium concentrations were measured over three periods of time: A from the first cross-clamp (during cardiopulmonary bypass) to the end of the operation, B during die first 6 h after operation and C during the next 18 h.
Magnesium concentrations in both plasma and urine were measured quantitatively by a methyl thymol-blue complexometric procedure using the DuPont ACA discrete clinical analyser. All urines were acidified before analysis. Within-run precision was 4.8% and 1.7% at magnesium concentrations of 0.96 and 8.11 mmol litre" 1 , respectively.
Twelve-lead electrocardiography was performed before, and repeated at 6 and 24 h after surgery. QT corr intervals were derived using the relationship: QTi/VRR where QTi is the measured QT interval and RR is the time interval between adjacent R waves. Evidence of myocardial infarction was based on the appearance of new Q waves, together with an increase in creatinine kinase (MB fraction) concentration to greater than 6 % of total creatinine kinase activity, when comparing a measurement at 24 h after operation widi the preoperative measurement.
The electrocardiogram was recorded continuously in the postoperative period, by means of an Oxford 24-h, single-channel tape recorder for subsequent off-line analysis of heart rate and rhythm using a Reynolds Pathfinder 3 Arrhythmia Analysis System. The tapes were analysed independently before the double-blind trial code was broken. Types of arrhythmia were recorded and an assessment made of the frequency of occurrence from the cardiology department reports on the 24-h tapes using their standard classification of absent, occasional or frequent.
Statistical differences between the groups were evaluated using an unpaired Student's t test and comparisons in the same individual with the paired t test.
RESULTS
Nine of the 20 patients in the study were given magnesium chloride, and 11 acted as controls. There were no significant differences between the groups with regard to age, body surface area, preoperative ejection fraction, number of distal coronary anastamoses, duration of cardiopulmonary bypass, aortic cross-clamp (myo- (table I) . There was also no significant difference in the mean values of preoperative plasma magnesium concentrations between groups, but at all other sample times the mean values in the control group were significantly lower (P < 0.001) than those in the magnesium-treated group. All mean values for plasma magnesium concentration after cardiopulmonary bypass in the control group were significantly lower than the preoperative values (P < 0.01) and remained below the normal reference range over the study period ( fig. 1) . Only three patients in the control group had values greater than 0.74 mmol litre"
1 at 24 h after surgery. In the magnesium-treated group, mean plasma magnesium concentrations were above the reference range following cardiopulmonary bypass until 1 h after operation, following which they remained within normal limits ( fig. 1 ). Individual patients in this group, however, were hypermagnesaemic for variable periods, and one patient still had an increased plasma magnesium concentration at 24 h (1.10 mmol litre" 1 )-No patient had a plasma magnesium in excess of 1.38 mmol litre"
1 . There was no significant difference between the groups for mean total urine output over 24 h. Three patients in the control group required an additional frusemide 20 mg during the postoperative period. The mean urinary concentration of magnesium was significantly higher (P < 0.01) in each of the three time periods in the magnesium group compared with the control group (table II) . Over 24 h, the control group excreted a mean total amount of magnesium 3.43 mmol compared with 12.17 mmol in the magnesium group. The difference represents 58% of the initial 16 mmol of magnesium given. I.v. fluid, calcium and potassium administration and serum calcium, and albumin concentrations were not significantly different between the groups. There were no significant differences between groups in the mean plasma potassium concentrations at any of the times it was measured in the study. Table III shows the mean plasma potassium values during the postoperative period.
Mean QT corr intervals did not alter significantly from preoperative values in either group during the study and there was no significant difference between groups (table IV) .
All patients were in baseline sinus rhythm after surgery. Three patients (one in the control group and two in the magnesium group) had no arrhythmia at all over 24 h. One patient in each group (both of whom exhibited frequent multifocal ventricular extrasystoles) subsequently de-veloped atrial fibrillation and both these patients were treated with an infusion of disopyramide. Five patients in the control group (45 %) and four in the magnesium group (44%) exhibited atrial extrasystoles. Seven patients in the control group (64%) and two patients in the magnesium group (22 %) exhibited frequent ventricular arrhythmias (ventricular extrasystoles, couplets, bigeminy and ventricular tachycardia). This difference was significant (P < 0.001). One patient in the control group, who had an episode of ventricular tachycardia, was treated with a lignocaine infusion. Although exact numerical analysis of the ectopic beats or couplets could not be attempted, all patients classified as having occasional arrhythmias had less than 10 over 24 h, while all those in the frequent group were considerably in excess of this.
Three patients in each group received inotropic agents for a short period after surgery. The drugs used were isoprenaline, dobutamine and adrenaline. Two patients required all three of these inotropes. One (in the magnesium group) remained in sinus rhythm, the other (in the control group) had frequent ventricular arrhythmias. The remaining four patients, two in each group, were given isoprenaline in order to increase heart rate and all of these patients exhibited both atrial and ventricular arrhythmias. No patient had evidence of perioperative myocardial infarction on the basis of the criteria defined in this study.
DISCUSSION
This study demonstrated that patients who did not receive magnesium during non-cardioplegic cardiopulmonary bypass were hypomagnesaemic for at least 24 h after the procedure. The intraoperative administration of magnesium chloride 16 mmol produced mean plasma magnesium concentrations that lay within the normal reference range between 1 and 24 h after surgery. Although individual patients in the magnesium group were hypermagnesaemic for variable periods, none was hypomagnesaemic at any time. These observations are in keeping with two separate studies which demonstrated dilutional hypomagnesaemia during cardiopulmonary bypass [12] and hypermagnesaemia following the administration of magnesium-containing cardioplegic solutions [13] .
The clinical importance of these results lies in the fact that myocardial preservation techniques, other than cardioplegic arrest, are used during coronary revascularization, in which case failure to administer magnesium to the patient could be expected to lead to postoperative hypomagnesaemia.
One of the suggested causes of hypomagnesaemia is excessive urinary loss, and there is some evidence to show that this can be appreciable [13, 15] . This study demonstrated that the total amount of magnesium excreted over the first 24 h after operation was greater in the magnesium-treated group, with the difference representing 58 % of the magnesium given during cardiopulmonary bypass. This figure is in agreement with previous work [13] . The fact that the administration of magnesium 16 mmol caused an increase in magnesium excretion over 24 h by a factor in excess of 3.5 over the control group, despite a similar diuresis, indicates that magnesium load and intraoperative haemodilution have greater influence on plasma magnesium concentration and urinary magnesium excretion than urine output per se.
Many different arrhythmias have been reported in association with magnesium deficiency, but ventricular tachyarrhythmias occur most frequently [3] . This may be related to the role of magnesium in the manufacture of membrane adenosine triphosphatase and, hence, maintenance of intracellular potassium [15] . Arrhythmias related to hypomagnesaemia may be refractory to any other therapy than the administration of i.v. magnesium [16] .
The incidence of atrial arrhythmias was similar in the two groups. However, the incidence of frequent ventricular arrhythmias in the control group, 64 %, was nearly three times greater than that found in the magnesium-treated group. This, coupled with the fact that hypomagnesaemia is particularly associated with ventricular tachyarrhythmias, suggests that failure to administer magnesium during operation may increase the potential for the development of ventricular arrhythmias during the first 24 h after coronary revascularization. It is appreciated that the number of patients studied was small and further investigation is in progress in order to confirm the effect of the administration of magnesium on the incidence of postoperative arrhythmia.
ECG changes seen in hypomagnesaemia (prolonged PR intervals, wide QRS complexes, depressed ST segments and inverted T waves) are very similar to those seen in hypokalaemia, and both may also be associated with a prolonged QT interval [15] . Prolongation of the QT interval itself is associated with an increase in arrhythmic potential. Other causes of a prolonged QT interval include hypocalcaemia, myocardial ischaemia and antiarrhythmic therapy [17, 18] . In this study every effort was made to reduce the influence of known factors (excluding plasma magnesium) on the QT corr . Thus patients on chronic antiarrhythmic therapy were excluded from the study and new myocardial ischaemia changes were not evident in any of the patients. Serum potassium and serum calcium concentrations were monitored closely and there was no significant difference between groups with regard to these measurements. In this study, we could demonstrate no effect on the QT corr interval associated with the administration of magnesium chloride during cardiopulmonary bypass, despite the wide variations in perioperative magnesium concentrations between the groups. Any arrhythmias observed in this study, therefore, occurred without electrocardiographic evidence of QT prolongation.
CONCLUSION
Following cardiopulmonary bypass without cardioplegic arrest, all control patients were found to be hypomagnesaemic for at least 24 h. Conversely, mild hypermagnesaemia in the immediate postoperative period, followed by normal plasma magnesium concentrations, were demonstrated in the first 24 h in those patients who received magnesium chloride 16 mmol during cardiopulmonary bypass. Fifty-eight percent of the magnesium given during bypass was excreted in the urine over the next 24 h, but hypomagnesaemia was not caused principally by excessive urinary loss. These observations were not associated with any significant differences in the duration of QT corr between patient groups.
Patients in the control group demonstrated a nearly three-fold incidence of frequent ventricular arrhythmias compared with the magnesiumtreated patients. Hypomagnesaemia may be one of the many contributory factors that predispose towards the development of postoperative arrhythmias, and the intraoperative administration of magnesium may reduce the incidence of potentially serious ventricular arrhythmias following coronary revascularization.
